• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Handl Therapeutics B.V.

The vision of Handl Therapeutics is to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases to begin addressing significant unmet medical needs in healthcare. The innovative business model is based on a highly integrative approach that is built on tight links with an international network of academic partners. Handl Therapeutics goal is to build a streamlined business that is designed to deliver transformative advanced medicines to the market. *

 

	Start	2019-10-01 established
	Group	UCB (Group)
	Industry	BIOTECH
	Industry 2	gene therapy
	Region	Leuven (Louvain)
	Country	Belgium
	Street	1 Gaston Geenslaan Bio-Incubator 3
	City	3001 Heverlee
	Tel	+32-470-555311
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�: UCB S.A.. (11/12/20). "Press Release: UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms". Brussels.
		Record changed: 2020-11-18

Advertisement

More documents for UCB (Group)

• [1] Swedish Orphan Biovitrum AB. (12/21/20). "Press Release: Sobi Appoints New Head of North America Ahead of Launch Phase"....
• [2] UCB S.A.. (11/12/20). "Press Release: UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms". Brussels....
• [3] UCB S.A.. (3/9/20). "Press Release: UCB Announces Appointment of Sandrine Dufour as New Chief Financial Officer". Brussels....
• [4] CRISPR Therapeutics AG. (2/26/20). "Press Release: CRISPR Therapeutics Proposes Changes to the Board of Directors". Zug & Cambridge, MA....
• [5] UCB S.A.. (10/10/19). "Press Release: UCB Agrees to Acquire Ra Pharmaceuticals". Brussels & Cambridge, MA....
• [6] Rinri Therapeutics Ltd.. (5/20/19). "Press Release: Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss". Sheffield....
• [7] UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels....
• [8] UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels....
• [9] UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels....
• [10] UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.